![[ID: Graphic featuring Avril Daly, CEO of Retina International, with a quote on patient-led innovation and measuring what matters, from a Pharma Boardroom interview.]](https://retina-international.org/wp-content/uploads/2026/09/Social-Graphics-2-13-819x1024.png)
Europe’s clinical trial landscape is changing and for people living with rare diseases, the stakes are enormous.
Europe’s share of global clinical trials has fallen from 22% to 12% since 2013, representing around 60,000 fewer clinical trial places. For the 95% of people living with rare diseases who have no approved treatment, access to a clinical trial can mean access to a potential therapy when few other options exist.
In a recent interview with Pharma Boardroom, our CEO Avril Daly explores what this changing landscape means for people living with rare and retinal diseases, from the growing pipeline of potential retinal therapies to the complex legislative changes shaping research and healthcare across Europe.
Avril also reflects on an encouraging shift within the rare disease community, from identifying problems to coming together to build solutions.
Read the full interview and hear Avril’s perspective on the future of clinical research, innovation and access across Europe – https://pharmaboardroom.com/interviews/avril-daly-ceo-retina-international-president-eurordis-rare-diseases-europe/
#RareDiseases #ClinicalTrials #RetinalDiseases #PatientVoice #PatientCentredResearch #HealthInnovation #ClinicalResearch
